2017-001463-21: MK-3682B in Hepatitis C Virus (HCV) Genotype 3 (GT3) participants |
|
|
| Ongoing | 3 | 426 | Europe | MK-3682B, MK-3682B, Tablet | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc | Treatment of hepatitis C virus (HCV) infection, Treatment of chronic hepatitis C virus (HCV) infection, Diseases [C] - Virus Diseases [C02] | | | | |
2016-000620-26: MK-3682B Fixed Dose Combination (FDC) in Subjects with Chronic Hepatitis C Virus (HCV) Infection |
|
|
| Ongoing | 2/3 | 160 | Europe | MK-3682B, MK-3682B, Tablet | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | Chronic Hepatitis C Infected Patient, Chronic Hepatitis C Infected Patient, Diseases [C] - Virus Diseases [C02] | | | | |
